View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
August 12, 2020updated 12 Jul 2022 11:39am

Mexico to conduct trials for US and Chinese Covid-19 vaccines

Mexico is reportedly planning to carry out late stage trials for coronavirus (Covid-19) vaccines being developed by companies in the US and China.

Mexico is reportedly planning to carry out late stage trials for coronavirus (Covid-19) vaccines being developed by companies in the US and China.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

Reuters reported Foreign Minister Marcelo Ebrard as saying in a news conference that Mexico has signed memorandums of understanding (MoU) with Johnson & Johnson (J&J), alongside China-based companies CanSino Biologics and Walvax Biotechnology.

According to the minister, the two countries might base some of their vaccine production in Mexico.

Ebrard noted that trials would start between September this year and January next year, subject to approval from Mexico’s food and drug agency.

He added that the goal was to secure drug access for Mexico, highlighting global ‘vaccine diplomacy’ as developing countries are struggling to get timely access to treatments and vaccines.

Ebrard was quoted by the news agency as stating: “This is what worries President (Andres Manuel) Lopez Obrador, that we have it on time.”

CanSino and Walvax showed interest in producing an ‘eventual vaccine’ in Mexico for the Latin American market, said the foreign ministry.

J&J could produce about one billion doses of the vaccine next year, if successful.

J&J executive said that the company would consider injecting healthy participants with the novel coronavirus if there are no enough patients for the final trials.

Meanwhile, the experimental vaccine of Walvax is currently undergoing early testing at a China-based military research institute, while CanSino Biologics’ vaccine candidate is already being studied.

CanSino is also collaborating with Canada’s national research and technology organisation National Research Council (NRC) for future trials in Canada.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena